Clinical Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al Moustafa, A.-E.
Right arrow Articles by O’Connor-McCourt, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al Moustafa, A.-E.
Right arrow Articles by O’Connor-McCourt, M.
Clinical Cancer Research Vol. 5, 681-686, March 1999
© 1999 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Up-Regulation of E-Cadherin by an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Lung Cancer Cell Lines1

Ala-Eddin Al Moustafa2, Cedric Yansouni, Moulay A. Alaoui-Jamali and Maureen O’Connor-McCourt

National Research Council Canada, Biotechnology Research Institute, Montréal, Québec, H4P 2R2 Canada and Department of Biochemistry, McGill University, Montréal, Québec, Canada [A-E. A., C. Y., M. O-M.]; and Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine and Oncology, and McGill Center for Translational Research in Cancer, Montréal, Québec, H3T 1E2 Canada [M. A. A-J.]

Many human epithelial carcinomas are characterized by the overexpression and constitutive activation of the epidermal growth factor receptor (EGF-R) via an autocrine signaling loop. We have investigated the effects of a ligand-blocking monoclonal antibody (mAb) against the EGF-R LA1 on selected parameters of human lung cancer cell lines (H322 and H661) and normal human bronchial epithelial (NHBE) cells. Using Western blot analysis, we show that H322 and NHBE cell lines express comparable levels of EGF-R/p170erbB-1. The LA1 mAb against EGF-R inhibits growth, induces differentiation to a more epithelial phenotype, reduces the constitutive activation of EGF-R, and up-regulates epithelial cadherin glycoprotein expression in H322 and NHBE cells. In contrast, LA1 had no effect on either growth, differentiation, receptor tyrosine phosphorylation, or the expression of adhesion molecules in H661 cells, which is consistent with our finding that this cell line does not express detectable levels of EGF-R. These studies demonstrate that a blocking anti-EGF-R mAb can regulate proliferation, differentiation, and the expression of cell adhesion molecules in human bronchial epithelial cells. Our findings suggest possible therapeutic avenues for the treatment of invasive carcinomas via the blockade of EGF-R with antibodies.




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. A. Nikolova, I. A. Asangani, L. D. Nelson, D. P.M. Hughes, D. R. Siwak, G. B. Mills, A. Harms, E. Buchholz, L. R. Pilz, C. Manegold, et al.
Cetuximab Attenuates Metastasis and u-PAR Expression in Non-Small Cell Lung Cancer: u-PAR and E-Cadherin are Novel Biomarkers of Cetuximab Sensitivity
Cancer Res., March 15, 2009; 69(6): 2461 - 2470.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Farley, D. E. Purdy, O. P. Ryabinina, P. Schneider, B. E. Magun, and M. S. Iordanov
Fas Ligand-induced Proinflammatory Transcriptional Responses in Reconstructed Human Epidermis: RECRUITMENT OF THE EPIDERMAL GROWTH FACTOR RECEPTOR AND ACTIVATION OF MAP KINASES
J. Biol. Chem., January 11, 2008; 283(2): 919 - 928.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. D. Woodworth, E. Michael, D. Marker, S. Allen, L. Smith, and M. Nees
Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment
Mol. Cancer Ther., April 1, 2005; 4(4): 650 - 658.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, S. Di Cosimo, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, et al.
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225): Superiority Over Single-Agent Receptor Targeting
Clin. Cancer Res., October 1, 2004; 10(19): 6487 - 6501.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. H. Lorch, J. Klessner, J. K. Park, S. Getsios, Y. L. Wu, M. S. Stack, and K. J. Green
Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells
J. Biol. Chem., August 27, 2004; 279(35): 37191 - 37200.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. M. Nguyen, S. Desai, A. Chen, T. S. Weiser, and D. S. Schrump
Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin
Ann. Thorac. Surg., December 1, 2000; 70(6): 1853 - 1860.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.